Company Valuation: Aprogen Biologics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 524,120 360,706 200,481 190,684 130,793 102,540
Change - -31.18% -44.42% -4.89% -31.41% -21.6%
Enterprise Value (EV) 1 322,016 238,252 236,145 361,628 246,492 279,703
Change - -26.01% -0.88% 53.14% -31.84% 13.47%
P/E 37.6x 45.3x 26.5x -1.55x -0.79x -0.6x
PBR 1.04x 0.71x 0.7x 0.52x 0.35x 0.49x
PEG - -1.1x -5.3x 0x 0x -0.18x
Capitalization / Revenue 9.83x 6.39x 3.08x 2.18x 1.94x 1.4x
EV / Revenue 6.04x 4.22x 3.62x 4.14x 3.66x 3.82x
EV / EBITDA 378x -125x -24x -7.34x -6.24x -2.7x
EV / EBIT -298x -59.9x -19.3x -5.12x -4.21x -2.28x
EV / FCF -10.8x -2.45x 2.37x 25.9x -10.3x -3.38x
FCF Yield -9.23% -40.8% 42.1% 3.87% -9.75% -29.6%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 5,250 3,000 2,850 -28,122 -12,525 -12,932
Distribution rate - - - - - -
Net sales 1 53,320 56,482 65,190 87,364 67,378 73,226
EBITDA 1 851.3 -1,903 -9,837 -49,292 -39,486 -103,705
EBIT 1 -1,081 -3,975 -12,241 -70,690 -58,577 -122,889
Net income 1 11,253 8,103 7,837 -118,270 -104,979 -170,331
Net Debt 1 -202,104 -122,454 35,664 170,944 115,698 177,163
Reference price 2 197,250.00 135,750.00 75,450.00 43,500.00 9,930.00 7,785.00
Nbr of stocks (in thousands) 2,657 2,657 2,657 4,384 13,172 13,172
Announcement Date 3/12/21 3/14/22 3/17/23 3/13/24 3/14/25 3/20/26
1KRW in Million2KRW
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 18.8M
32.45x11.78x23.93x0.61% 1,019B
28.48x6.32x17.7x2.09% 617B
33.26x7.78x16.08x2.64% 464B
104.98x5.87x24.89x2.36% 356B
18.81x4.58x11.36x2.9% 333B
19.83x5.17x12.78x3.09% 267B
20.02x4.17x11.86x2.13% 244B
25.46x6.66x11.86x2.5% 218B
-43.78x6.39x24.97x2.27% 179B
Average 26.61x 6.52x 17.27x 2.29% 369.72B
Weighted average by Cap. 31.80x 7.61x 18.61x 1.96%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. A003060 Stock
  4. Valuation Aprogen Biologics Inc.